Tagged as: Shanghai Junshi Biosciences Co. Ltd.

FDA Approves LOQTORZI in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma

On October 27, Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. Food and Drug Administration approved LOQTORZI (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment…

Read More